Epilepsy and Mood Regulation Disorder in Children (EPILETRE)
Primary Purpose
Epilepsy
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Multiscore Depression Inventory for Children scale
Sponsored by
About this trial
This is an interventional supportive care trial for Epilepsy focused on measuring epilepsy, depression, mood disorder, anxiety, cyclothymia, Behavioral neuropsychiatric features
Eligibility Criteria
Inclusion Criteria:
- one of the following 3 epilepsy categories (focal structural epilepsy, with or without (MRI-negative) detectable cerebral lesion; focal idiopathic (genetic) epilepsy; generalized idiopathic (genetic) epilepsy).
- Onset of epilepsy within the 6 months from enrolment.
- Patients whose eventual antiepileptic drug treatments were not modified in the months preceding the neuropsychological and psychiatric evaluations.
- Patients who give their consent to participate in the study and whose legal guardians have agreed to sign the written consent form.
Exclusion Criteria:
- Patients younger than 5 years and 11 months or older than 15 years and 6 months.
- Patients with a diagnosis of epilepsy, other than the types defined above.
- Cognitive impairment, defined as a score of <70, based on WISC-IV verbal comprehension and perceptual reasoning scales.
- Children with a confirmed diagnosis of a psychiatric disorder, other than those studied.
Sites / Locations
- Hôpital Femme Mère EnfantRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Scales passation
Arm Description
Outcomes
Primary Outcome Measures
Number of children with new- or recent-onset epilepsy with a pathological score in a least one of the 3 scales
The 3 scales are MDI-C ; R-CMAS and Kochman scale :
A standard score of >66 for MDI-C (Multiscore Depression Inventory for Children) indicating a depressive disorder;
A standard score of >60 or <40 for R-CMAS (Revisited Children's Manifest Anxiety Scale) indicating an anxiety disorder;
A score of >12 for Kochman indicating a cyclothymia disorder
Secondary Outcome Measures
Correlate pathological scores obtained with the type of epilepsy
The same scoring system as for the primary end point will be used
Type of epilepsy :
with or without (MRI-negative) detectable cerebral lesion;
focal idiopathic (genetic) epilepsy;
generalized idiopathic (genetic) epilepsy).
Correlate pathological scores with the progression of epilepsy disease
The same scoring system as for the primary end point will be used to evaluate the development, or progression, of emotional regulation disorders after 18 months of follow-up (constituted epilepsy);
In each types of epilepsy, progression of the disease will be assessed by :
crises frequency
crises type
Full Information
NCT ID
NCT02568813
First Posted
September 30, 2015
Last Updated
September 12, 2019
Sponsor
Hospices Civils de Lyon
1. Study Identification
Unique Protocol Identification Number
NCT02568813
Brief Title
Epilepsy and Mood Regulation Disorder in Children
Acronym
EPILETRE
Official Title
Epilepsy and Mood Regulation Disorders: a Prospective and Longitudinal Study in Children With Newly Diagnosed Epilepsy
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 30, 2015 (Actual)
Primary Completion Date
April 30, 2022 (Anticipated)
Study Completion Date
April 30, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Epilepsy is a multifaceted disorder and a major public health problem. In addition to recurrent and unpredictable seizures, abnormalities in psychiatric status, cognition and social-adaptive behaviors are potential major sources of disability in children and adults with epilepsy disorders. Recent studies have unequivocally documented raised psychiatric comorbidities in children with epilepsy, particularly emotional regulation disorders such as depression and anxiety, as compared to both the general population and the children with other medical disorders, neurological and non-neurological. A prevalence of 12% to 35% has been reported, compared to 3-8% in the general population.
Major advances have begun to uncover the potential mediators of emotional regulation disorders and social comorbidities in epilepsy, but important gaps remain in the early detection, treatment and prevention of these disorders. A very small number of investigations have examined children with epilepsy at or near the time of diagnosis. This is a time during which the effects of chronic epilepsy, potential averse social effects of epilepsy, and other complicating aetiological effects are minimized.
Epilepsy syndromes provide a useful framework for considering the risk and type of emotional dysregulation comorbidities. But variability within and across syndromes needs to be taken into account thus requiring a strict phenotyping by specialists in the filed of pediatric epileptology. Retrospective studies, usually including patients with chronic epilepsies and suffering from a mixed spectrum of epilepsy syndromes introduce biases leading to rather disparate findings.
Are such disorders the result of common physiopathological mechanisms, which precede the development of the epilepsy? The link between an underlying brain disorder and psychiatric comorbidities has emerged in recent literature, with evidence based on studies in adults, suggesting bidirectional relations between epilepsy and neurobehavioural comorbidities. Emotional regulation disorders can follow the onset of epilepsy, but they can also precede it, thus serving as a possible risk factor. The clinical implication of such a bidirectional association is that neurobehavioural comorbidities might be present at diagnosis and even before epilepsy onset. There is a need for greater understanding of the causes of these conditions in younger people.
The degree to which specific epilepsy syndromes are associated with the relative risk of emotional dysregulation disorders in children with new- or recent-onset (within six months prior to enrolment) has rarely been comprehensively examined and represents the focus of the current investigation.
The investigators study will be based on a prospectively recruited cohort of 280 children/adolescents with recently diagnosed epilepsy. All participating centres dispose of the necessary competences for a precise diagnosis of the epilepsy syndromes and the tools for a per case appropriate aetiology screening. Following a first seizure children are usually first examined at hospital based emergency departments. Prompt referral to the epilepsy teams participating at the present study will significantly reduce the population biases and shortcuts encountered in studies that recruited patients with chronic epilepsy followed in tertiary care epilepsy units.
The investigators expect their results to provide a greater understanding of both the shared and the unique features of emotional regulation disorders, in relation to specific epilepsy categories defined on the basis of the underlying physiopathological mechanisms.
Such knowledge will also assist clinicians and families in the planning of both diagnosis and management resources.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
epilepsy, depression, mood disorder, anxiety, cyclothymia, Behavioral neuropsychiatric features
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Scales passation
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Multiscore Depression Inventory for Children scale
Other Intervention Name(s)
Revisited Children's Manifest Anxiety Scale, Kochman indicating a cyclothymia disorder Scale, Weschler Intelligence Scale for Children - 4th Edition
Primary Outcome Measure Information:
Title
Number of children with new- or recent-onset epilepsy with a pathological score in a least one of the 3 scales
Description
The 3 scales are MDI-C ; R-CMAS and Kochman scale :
A standard score of >66 for MDI-C (Multiscore Depression Inventory for Children) indicating a depressive disorder;
A standard score of >60 or <40 for R-CMAS (Revisited Children's Manifest Anxiety Scale) indicating an anxiety disorder;
A score of >12 for Kochman indicating a cyclothymia disorder
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Correlate pathological scores obtained with the type of epilepsy
Description
The same scoring system as for the primary end point will be used
Type of epilepsy :
with or without (MRI-negative) detectable cerebral lesion;
focal idiopathic (genetic) epilepsy;
generalized idiopathic (genetic) epilepsy).
Time Frame
18 months
Title
Correlate pathological scores with the progression of epilepsy disease
Description
The same scoring system as for the primary end point will be used to evaluate the development, or progression, of emotional regulation disorders after 18 months of follow-up (constituted epilepsy);
In each types of epilepsy, progression of the disease will be assessed by :
crises frequency
crises type
Time Frame
18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
one of the following 3 epilepsy categories (focal structural epilepsy, with or without (MRI-negative) detectable cerebral lesion; focal idiopathic (genetic) epilepsy; generalized idiopathic (genetic) epilepsy).
Onset of epilepsy within the 6 months from enrolment.
Patients whose eventual antiepileptic drug treatments were not modified in the months preceding the neuropsychological and psychiatric evaluations.
Patients who give their consent to participate in the study and whose legal guardians have agreed to sign the written consent form.
Exclusion Criteria:
Patients younger than 5 years and 11 months or older than 15 years and 6 months.
Patients with a diagnosis of epilepsy, other than the types defined above.
Cognitive impairment, defined as a score of <70, based on WISC-IV verbal comprehension and perceptual reasoning scales.
Children with a confirmed diagnosis of a psychiatric disorder, other than those studied.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexis ARZIMANOGLOU, Pr
Phone
(0)4 27 85 77 04
Ext
+33
Email
aarzimanoglou@orange.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Agathe LAURENT,, PhD
Phone
(0)6 61 60 11 30
Ext
+33
Email
agathelaurent1977@gmail.com
Facility Information:
Facility Name
Hôpital Femme Mère Enfant
City
Bron
State/Province
Rhône
ZIP/Postal Code
69500
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexis ARZIMANOGLOU, Pr
Phone
(0)4 27 85 77 04
Ext
+33
Email
aarzimanoglou@orange.fr
First Name & Middle Initial & Last Name & Degree
Agathe LAURENT, PhD
Phone
(0)6 61 60 11 30
Ext
+33
Email
agathelaurent1977@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Epilepsy and Mood Regulation Disorder in Children
We'll reach out to this number within 24 hrs